About MannKind
MannKind (NASDAQ:MNKD) is dedicated to discovering, developing, and commercializing innovative therapeutic products for patients with diseases such as diabetes. Central to its portfolio is Afrezza, an inhalable insulin offering a unique administration method compared to traditional insulin delivery mechanisms, aimed at improving the quality of life for those managing their diabetes. Beyond diabetes, MannKind is exploring opportunities to leverage its technosphere technology platform to create inhalable therapeutic products for other conditions. Their objective is to expand the application of their technology to address unmet medical needs across various diseases, pushing the boundaries of what's possible in medical science and improving patient outcomes.
Snapshot
Operations
Produtos e/ou serviços de MannKind
- Afrezza, an inhalable insulin for adults with diabetes, offers a rapid-acting mealtime blood sugar control alternative.
- Technosphere technology, a versatile pulmonary drug delivery platform designed to improve medication efficacy and patient compliance.
- Tyvaso DPI, developed in collaboration with United Therapeutics for pulmonary arterial hypertension, leverages Technosphere for targeted delivery.
- Epalrestat inhalation powder, an investigational treatment for diabetic peripheral neuropathy, aiming to reduce symptoms and progression.
- Collaboration with Vertice Pharma to create inhalable treatments for orphan lung diseases, expanding therapeutic options for rare conditions.
- MannKind is exploring inhaled therapeutic options for oncology, aiming to develop innovative treatments for cancer patients.
equipe executiva do MannKind
- Dr. Michael E. Castagna Pharm.D.CEO & Director
- Mr. Christopher B. Prentiss M.B.A.Chief Financial Officer
- Dr. David B. Thomson J.D., Ph.D.Executive VP, General Counsel & Secretary
- Mr. Sanjay Singh M.B.A.Executive Vice President of Technical Operations
- Dr. Stuart A. Tross Ph.D.Chief People & Workplace Officer
- Mr. Dominic Marasco R.Ph.President of Endocrine Business Unit
- Dr. Ajay Ahuja M.B.A., M.D.Chief Medical Officer